行情

SCYX

SCYX

SCYNEXIS
NASDAQ

实时行情|Nasdaq Last Sale

0.7445
-0.0456
-5.77%
交易中 15:19 12/12 EST
开盘
0.7800
昨收
0.7901
最高
0.7941
最低
0.7241
成交量
77.27万
成交额
--
52周最高
1.900
52周最低
0.3500
市值
4,270.63万
市盈率(TTM)
-1.0279
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SCYX 新闻

  • SCYNEXIS Announces Closing of $35 Million Public Offering of Common Stock and Warrants
  • PR Newswire.2小时前
  • The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
  • Benzinga.2天前
  • The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
  • Benzinga.2天前
  • Scynexis prices equity offering
  • Seeking Alpha - Article.2天前

更多

所属板块

制药
+0.63%
制药与医学研究
+0.70%

热门股票

名称
价格
涨跌幅

SCYX 简况

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
展开

Webull提供SCYNEXIS Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。